Expertise in
10
conditions

Dr. Jason E. Tache

Oncology
South Florida Oncology And Hematology Consultants LLC
8200 W Sunrise Blvd Bldg C, 
Plantation, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
10
conditions
South Florida Oncology And Hematology Consultants LLC
8200 W Sunrise Blvd Bldg C, 
Plantation, FL 

Overview

Jason Tache is an Oncologist practicing medicine in Plantation, Florida.

Dr. Tache is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Chronic Myelogenous Leukemia (CML), Philadelphia-Negative Chronic Myeloid Leukemia, Venous Thromboembolism (VTE), Thrombocytopenia, and Orchiectomy.

He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 11 clinical trials. Dr. Tache is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in FL

Hospital Affiliations

Broward Health Medical Center
Memorial Hospital West
Memorial Hospital Pembroke
Westside Regional Medical Center

Languages Spoken

English
Hebrew
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

South Florida Oncology and Hematology Consultants LLC
8200 W Sunrise Blvd Bldg C, Plantation, FL 33322
Other Locations
Office
7351 W Oakland Park Blvd Ste 106, Tamarac, FL 33319

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 2b, Open-label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of an Immunotherapeutic Treatment DPX-Survivac and Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (VITALIZE)
A Phase 2b, Open-label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of an Immunotherapeutic Treatment DPX-Survivac and Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (VITALIZE)
Enrollment Status: Recruiting
Publish Date: April 07, 2023
Intervention Type: Drug
Study Drugs: DPX-Survivac, Pembrolizumab, CPA
Study Phase: Phase 2
A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
Enrollment Status: Completed
Publish Date: March 18, 2026
Intervention Type: Drug, Device
Study Drug: Immune checkpoint inhibitors or docetaxel
Study Phase: Phase 3
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: January 21, 2026
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Enrollment Status: Completed
Publish Date: October 31, 2025
Intervention Type: Device, Other
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
Enrollment Status: Terminated
Publish Date: April 10, 2025
Intervention Type: Drug
Study Drugs: SY-1425+Azacitidine, Azacitidine
Study Phase: Phase 3
Tamibarotene in Combination With Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-positive AML Who Are Ineligible for Standard Induction Therapy
Tamibarotene in Combination With Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-positive AML Who Are Ineligible for Standard Induction Therapy
Enrollment Status: Terminated
Publish Date: February 24, 2025
Intervention Type: Drug
Study Drugs: Tamibarotene, Venetoclax, Azacitidine
Study Phase: Phase 2
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drugs: Selinexor, Bortezomib, Dexamethasone
Study Phase: Phase 3
A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination With Toripalimabin Subjects With Advanced Solid Malignancies Including Lymphoma
A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination With Toripalimabin Subjects With Advanced Solid Malignancies Including Lymphoma
Enrollment Status: Unknown
Publish Date: February 05, 2024
Intervention Type: Drug
Study Drugs: TAB004, Toripalimab
Study Phase: Phase 1
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 3
View 9 Less Clinical Trials

1 Total Publications

An Extremely Rare Manifestation of Multiple Myeloma: An Immunoglobulin D Secreting Testicular Plasmacytoma.
An Extremely Rare Manifestation of Multiple Myeloma: An Immunoglobulin D Secreting Testicular Plasmacytoma.
Journal: Cureus
Published: August 29, 2017
Similar Doctors
Expertise in
58
conditions
Dr. Ricardo J. Komotar
Oncology | Neurosurgery
Expertise in
58
conditions
Dr. Ricardo J. Komotar
Oncology | Neurosurgery
Referral may be required
1295 Northwest 14th Street, 
Miami, FL 
 (25.3 miles away)
305-243-6946
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ricardo Komotar is an Oncologist and a Neurosurgery provider practicing medicine in Miami, Florida. Dr. Komotar is highly rated in 58 conditions, according to our data. His clinical expertise encompasses Brain Tumor, Meningioma, Glioblastoma, Awake Craniotomy, and Posterior Fossa Decompression. Dr. Komotar is currently accepting new patients.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

Baptist Health Miami Cancer Institute

8900 N Kendall Dr, 
Miami, FL 
 (32.6 miles away)
786-345-7208
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Manmeet Ahluwalia is an Oncologist practicing medicine in Miami, Florida. Dr. Ahluwalia is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Brain Tumor, Glioblastoma, Astrocytoma, and Glioma. Dr. Ahluwalia is currently accepting new patients.

Expertise in
13
conditions
Dr. Luis E. Raez
Hematology | Oncology
Expertise in
13
conditions
Dr. Luis E. Raez
Hematology | Oncology
Referral may be required

Memorial Cancer Institute

12235 Pines Blvd, 
Pembroke Pines, FL 
 (8.8 miles away)
954-869-5708
Languages Spoken:
English, Portuguese, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Luis Raez is a Hematologist and an Oncologist practicing medicine in Pembroke Pines, Florida. Dr. Raez is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Lung Adenocarcinoma, and Tissue Biopsy. Dr. Raez is currently accepting new patients.

Frequently Asked Questions about Dr. Jason E. Tache

How do I make an appointment with Dr. Jason E. Tache?

You can book an appointment with Dr. Jason E. Tache by calling their office at 954-370-8585. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jason E. Tache a top-rated expert for Chronic Myelogenous Leukemia (CML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jason E. Tache is classified as an Advanced expert for Chronic Myelogenous Leukemia (CML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jason E. Tache specialize in?

While Dr. Jason E. Tache is a Oncology, they have specific expertise in Chronic Myelogenous Leukemia (CML), Philadelphia-Negative Chronic Myeloid Leukemia, and Venous Thromboembolism (VTE). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Jason E. Tache participate in research or clinical trials?

Yes. Dr. Jason E. Tache has published 1 articles and abstracts on conditions like Chronic Myelogenous Leukemia (CML). You can view a list of Dr. Jason E. Tache's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jason E. Tache accept my insurance?

Dr. Jason E. Tache accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 954-370-8585 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tache's expertise for a condition
ConditionClose
      View All 10 Advanced Conditions
      View All 66 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile